Περίληψη:
The role of low levels of HDV-RNA during and after interferon therapy of hepatitis D is unknown. We re-analysed HDV RNA in 372 samples collected in the HIDIT-2 trial (Wedemeyer et al, Lancet Infectious Diseases 2019) with the Robogene assay (RA; Jena Analytics). Data were compared with the previously reported in-house assay (IA). We detected HDV-RNA in one-third of samples previously classified as undetectable using the highly sensitive RA. Low HDV viraemia detectable at week 48 or week 96 was associated with a high risk for post-treatment relapse, defined as HDV RNA positivity in both assays at week 120. HDV RNA relapses occurred in 10/15 (67%) patients with detectable low HDV RNA at week 48 and in 10/13 (77%) patients with low viraemia samples at week 96. In contrast, the post-treatment relapse rate was lower in patients with undetectable HDV RNA in both assays during treatment. © 2020 The Authors. Liver International published by John Wiley & Sons Ltd
Συγγραφείς:
Bremer, B.
Anastasiou, O.E.
Hardtke, S.
Caruntu, F.A.
Curescu, M.G.
Yalcin, K.
Akarca, U.S.
Gürel, S.
Zeuzem, S.
Erhardt, A.
Lüth, S.
Papatheodoridis, G.V.
Radu, M.
Idilman, R.
Manns, M.P.
Cornberg, M.
Yurdaydin, C.
Wedemeyer, H.
Λέξεις-κλειδιά:
alanine aminotransferase; aspartate aminotransferase; peginterferon alpha2a; tenofovir disoproxil; virus RNA, antiviral therapy; Article; combination drug therapy; controlled study; disease association; follow up; hepatitis D; human; infection risk; limit of detection; major clinical study; null result; predictive value; recurrence risk; RNA analysis; viremia; virus load
